Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 1:10 PM
Ignite Modification Date:
2025-12-24 @ 1:10 PM
NCT ID:
NCT07071961
Brief Summary:
To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
Detailed Description:
Primary Objectives
• To determine the 6-month circulating tumor (ctDNA) clearance rate following 6 months of therapy with RELO regimen in patients with colorectal cancer (CRC) who present with radiographic occult molecular residual disease (MRD) after completing definitive standard-of-care (SOC) therapy.
Secondary Objectives
* To determine the 3-month ctDNA clearance rate following RELO treatment.
* To determine disease-free survival (DFS) following 6 months of RELO treatment.
* To determine overall survival (OS) following 6 months of RELO treatment.
* To determine the safety and tolerability of RELO.
Study:
NCT07071961
Study Brief:
Protocol Section:
NCT07071961